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1. Introduction
Nuclear Medicine is a medical specialty in which radioactive substances are used for diag‐
nostic and therapeutic purposes. Historically, its major development occurred after the Sec‐
ond World War. After the attack on Pearl Harbor, the United States developed nuclear
reactors to produce atomic bombs, which were subsequently dropped on the Japanese cities
of Hiroshima and Nagasaki. After the end of the war, the United States was involved in the
campaign for application of Atomic Energy for Peace, which stimulated implementation of
knowledge of nuclear energy for medical applications, among other beneficial actions. There
is no doubt that this was the greatest advance in the production and distribution of radionu‐
clides for medical purposes. The first radionuclide for medical applications was iodine-131,
and this was followed by several others. Artificial production of technetium for diagnostic
purposes was a milestone in the history of nuclear medicine. Today, this radioisotope is
used the one most for producing imaging.
In the beginning, the images were documented using rectilinear scanner and subsequently
using scintillation cameras or so-called gamma cameras, with images of poor definition.
With technological development, improvements to gamma cameras became possible. The
acquisition of functional images, which had previously only been done on a two-dimension‐
al plane, became tomographic with three-dimensional reconstruction. This was named Sin‐
gle-Photon Emission Computed Tomography (known as SPECT), and it increased the
sensitivity of detecting abnormalities or lesions. More recently, gamma cameras have been
coupled with computed tomography (CT) or magnetic resonance imaging (MRI), thereby
forming hybrid machines and increasing the effectiveness of identifying lesions or function‐
ally abnormal tissues, at their sites. Technological advances have also been important for
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Positron Emission Tomography (known as PET), thereby massively increasing the applica‐
bility of this method, especially related to oncologic processes, with molecular imaging.
The diagnostic and therapeutic applications are based on the kind of radiation used. In general,
gamma emitters are used for diagnosis, and technetium-99m is the most common agent for this
purpose. For therapy, beta radiation emitters such as iodine-131 are the agents most used.
Scintigraphy is a noninvasive imaging diagnosis method using low doses of radiation, it is
painless, has reasonable cost and availability, and enables functional or metabolic assess‐
ment of organs or structures. Its advantage is clear, especially when the possibility of analy‐
sis using other methods is limited. It is based on administration of radiation-emitting
substances to patients, with detection by scanning using a scintillation camera. These radio‐
active substances may migrate to the organs themselves or, when that does not happen, they
may bind to other substances, thus forming complexes called radiopharmaceuticals that are
taken up by the target organ. There are specific pharmaceuticals for each organ, e.g. MDP,
DTPA, sestamibi, etc., thus making it possible to perform bone, renal or cardiac scintigra‐
phy, respectively. The great majority of radiotracers represent the physiology or metabolic
activity of some part of the body, but without altering the function of these structures or
forming part of the metabolism.
The main characteristic of scintigrams is that they provide information on the functioning
and metabolism of organs and structures. Hence, they differ from other imaging methods
such as ultrasound, CT scans or MRI, which are anatomical, and thus complement the diag‐
nostic investigation.
From this perspective, it is important to distinguish between the diagnostic approaches for
benign or malignant diseases. In benign lesions, the most important information comes from
functional assessment of each organ. This may show that the organ function is normal or is
deviating from normal, and this is assessed together with the evolution of the disease or the
post-intervention changes. Malignancies are assessed based on metabolic activity and find‐
ings of active primary or metastatic tumors. Details relating to residual tumors, viable tu‐
mors, recurrence, or disease progression are important and can be differentiated. Based on
this information, the clinical application of nuclear medicine is to highlight the physiological
or metabolic structures or organs involved.
This chapter does not aim to teach the methodology for performing scintigraphy, but to pro‐
vide some knowledge for professionals who are not specialists in this field, so that the use‐
fulness of this method in relation to various diseases can be seen.
This chapter is divided into applications and therapy using conventional scintigraphy with
single-photon emitters.
The radionuclide most used for performing single-photon scintigraphy is technetium 99m,
which is a pure gamma radiation emitter, with energy of 140 keV. This is considered to be a low
energy level with ideal characteristics for producing images. It can be administered alone or
coupled with pharmaceuticals to form complexes with specific characteristics relating to the
preferential uptake for various human organs or structures. For each type of scintigraphy,
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there is a specific radiotracer uptake mechanism that interfaces with the metabolism or excre‐
tion of the organ. In the following, most of the applications of diagnostic nuclear medicine in
different systems of the human body are presented. The general precautions to be taken in cas‐
es of pregnancy, breastfeeding, breastfed infants and young children, for all the procedures in
nuclear medicine, are indicated. This should be discussed on a case-by-case basis.
2. Gastrointestinal system
Application of nuclear medicine to the gastrointestinal (GI) system is very useful for investi‐
gating many diseases. This is a noninvasive and painless examination, with administration
of low doses of radiation to patients. It is easy to perform and is indicated for diagnosing
and following up gastrointestinal diseases. The long acquisition time for most examinations
increases the sensitivity for detecting gastrointestinal abnormalities. Scintigraphy is general‐
ly of use for assessing organ function and the kinetics of gastrointestinal transit or excretion.
2.1. Salivary gland imaging
This assesses the function and excretion of the salivary glands, both in the initial diagnosis
and in post-treatment follow-up. The main indications include: tumors, cysts, inflammatory
or infectious diseases, calculosis and Sjögren’s syndrome.
The radioisotope used is pertechnetate, an anion that is concentrated and secreted by the ep‐
ithelial cells of the salivary glands in the same way as seen with the anions that make up the
saliva. Thus, this substance reflects the production and physiological secretion of the saliva.
This radiotracer is administered intravenously, and sequential images of the head are ac‐
quired for 30 minutes. Over the first ten minutes, increasing concentration of radiotracer in
the salivary glands is observed, which represents the function. After administration of citric
stimulus, generally using lemon, the excretion phase begins. The uptake peak usually occurs
five to ten minutes after starting to administer the radiotracer, and complete excretion be‐
gins immediately after the stimulation with lemon (Figure 1).
 
Figure 1. Normal salivary gland imaging. Dynamic images are performed during 30 minutes and citric stimulus is on first fif‐
teen minutes. Region of interest are placed on right and left parotid (red and dark blue) and submandibulary (yellow and
light blue) glands and time activity curves are created showing quantitative uptake and excretion analyses.
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The scintigraphic abnormalities depend on the type and severity of disease. Most tumors
present diminished or absence of uptake radiotracer, except for Warthin’s tumor. Acute in‐
flammatory and infectious diseases present uptake increased because of the increased vas‐
cularization and diminished secretion. Abscesses and cysts do not show any uptake.
Patients with Sjögren’s syndrome either do not concentrate radioactive material or concen‐
trate very little of it (Figure 2).
 
Figure 2. Anormal salivary gland imaging. Absence uptake and non excretion in parotid glands confirmed by quanti‐
tative curves by region of interest (red and dark blue).
Other agents that are used to assess the salivary glands include gallium-67 and 111 In/
99mTc-labeled white blood cells, in cases of inflammatory or infectious diseases.
2.2. Scintigraphy on esophageal transit and emptying
Scintigraphy on the  esophageal  transit  is  a  noninvasive  examination with  oral  adminis‐
tration of radiotracer that supplies information on esophageal motility, in relation to the
duration  of  esophageal  transit  and  segmental  motor  abnormalities  such  as  adynamia
and  lack  of  coordination.  It  is  indicated  for  patients  with  suspected  primary  or  secon‐
dary motor disorders,  both for diagnosis and for follow-up of therapeutic interventions,
in  conditions  such  as  achalasia,  scleroderma,  diffuse  esophageal  spasm,  nutcracker
esophagus,  diabetic  enteropathy,  nonspecific  motor  disorders,  Chagas’  disease,  neo‐
plasm, systemic lupus erythematosus, polymyositis,  myasthenia gravis,  myotonic dystro‐
phy,  esophagitis,  alcoholism  and  others.  The  radiopharmaceuticals  indicated  for  these
assessments are those that are not absorbed by the esophageal mucosa,  such as colloids
and  chelates:  technetium-99mTc-sulfur  colloid  and  diethylenetriamine  pentaacetic  acid
(DPTA).  The  radiopharmaceuticals  are  administered  orally,  diluted  in  10  ml  of  water,
and deglutition is stimulated every 20 seconds with the patient in either a supine or an
upright  position.  The  transit  time  for  the  entire  esophagus  and  in  its  three  segments
(upper,  middle  and  lower)  is  quantified  and  the  motor  abnormality  pattern  (adynamia
or lack of coordination) is determined (Figure 3).
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 Figure  3.  Scintigraphy  on  esophageal  transit.  Normal,  adynamia  and  adynamia  with  incordination  patterns,  re‐
spectivelly.
2.3. Investigation of gastroesophageal reflux
Scintigraphy is the most sensitive noninvasive method for detecting gastroesophageal re‐
flux, especially in children. Colloids with low absorption rates in the esophageal and gastric
mucosa are used, thereby reflecting the kinetics of the tracer within the digestive system. Af‐
ter oral administration of 99mTc colloid, and with a field of view covering the stomach and
esophagus, episodes of gastroesophageal reflux are identified and information on the quan‐
tity and duration of the reflux and the point that it reaches are obtained (Figure 4). It has the
advantage of continuous and more prolonged acquisition, which increases the sensitivity of
the method. Other additional information obtained includes assessment of pulmonary aspi‐
ration, in the event that the reflux of the ingested material reaches the pulmonary tree.
Figure 4. Gastroesophageal reflux scintigraphy. A single episode with a short time, reaching the upper esophageal
segment (black arrow) and during a long time (red arrow).
2.4. Gastric emptying
This is a noninvasive examination performed after intake of solid foods, liquids or a mixture
of these. The emptying time and kinetics of the radiotracer in the stomach depend on the
composition of the food ingested. Several pharmacological materials can be labeled with the
radioactive substance, and the composition of both the food and the radiotracer depends on
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the standard adopted by each laboratory as the reference value. Computer acquisition is re‐
quired to determine the half-time of emptying and/or percent of emptying and to generate
gastric emptying time-activity curves. The main indications include diabetic gastroparesis,
anorexia nervosa, gastroesophageal reflux, gastritis, gastric ulcer, duodenal ulcer, Zollinger-
Ellison disease, connective tissue disorders and others, along with postsurgical evaluations,
vagotomy and gastrectomy.
2.5. Liver-spleen imaging
Other imaging methods such as MRI, CT and ultrasound offers better information about the
anatomic display of liver and spleen than does this exam. The radionuclide colloid imaging
is capitalized by phagocitosis by Kupffer cells of liver and spleen. The uptake and distribu‐
tion of 99mTc-colloid in liver and spleen reflects perfusion and the distribution of functioning
reticulendothelial cells. Usually, the information of liver-spleen scan include the size, shape
and position, the distribution aspect of activity within the organs, as homogeneity or non-
homogeneity, presence of any or many focal defects in activity and relative distribution of
colloid among the liver, spleen and bone marrow. Most of the masses seen on MRI, CT or
US, which take up 99mTc colloid contain Kupffer cells, and are benign. These present with
increased hepatic uptake and include: focal nodular hyperplasia (Figure 5), cirrhosis with re‐
generating nodule, Budd-Chiari syndrome and Superior vena caval obstruction. Masses
with decreased hepatic uptake can be benign or malignant. These include: hepatoma, meta‐
stasis, cyst, adenoma, hemangioma, abcess, and pseudotumor. The most common causes of
focal defects in the spleen include: abcess, cyst, infarct, lymphoma, and hematoma.
Figure 5. Liver-spleen scintigraphy. Focal nodular hyperplasia. Anterior and posterior images. Focal uptake increased
in liver (black arrow). Spleen increased too (red arrow).
2.6. Hepatic blood pool imaging
This exam is indicated for evaluating hemangiomas. These lesions are clusters or large blood
filled sinuses. They are usually asymptomatic, and are found as incidental findings during
MRI, CT or US performed for others indications. The radiotracer used is 99mTc-red blood
cells (RBC), injected intravenously. The typical appearance of 99mTc-RBC scan is a focal area
of decreased perfusion on the first study (flow phase), and in the immediate images because
the flow with 99mTc-RBC is relatively low compared to the hemangioma. About 1 or 2 hours
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later, the radiolabelled cells reach the hemangioma vessels, and then these lesions present as
a focal hot spot, with intensity similar to the heart. This method is highly specific to confirm
hemangioma.
2.7. Gastrointestinal bleeding imaging
The common causes of lower GI bleeding in adults include neoplasms, inflammatory bowel
disease, diverticular disease and angiodysplasia. The GI Imaging is a noninvasive method
that provides information especially of lower GI bleeding. The effective therapy for acute GI
bleeding depends on accurate localization of the site of bleeding. There are two radiotracer
that localize the GI bleeding; 99mTc-RBC and 99mTc-colloid. The first one is preferred in the
investigation of GI hemorrhage, especially in cases of intermittent or slow bleeding, because
the radiotracer remains in the intravascular space. Imaging may be performed over a period
of 24 hours. The second one is high, specifically to identify the bleeding site, but the sensitiv‐
ity is low, because it is performed for a short time and the bleeding needs to be present at
the moment of scintigraphy.
3. Cardiovascular system
Nuclear medicine examinations play an important role in the noninvasive evaluation of car‐
diac physiology.
3.1. Myocardial perfusion imaging
Myocardial perfusion imaging (MPI) has high sensitivity to evaluate perfusion in the left
ventricular wall and thus indirectly assess coronary flow. The ischemic cascade is the basis
and the best justification for the use of nuclear medicine examinations in the evaluation of
coronary artery disease.
Myocardial perfusion imaging can be performed with thallium-201 chloride and Pharma‐
ceuticals labelled with 99mTc (sestamibi, tetrofosmim and teboroxime). To use thallium-201
chloride it is necessary to fast for at least 4 hours. Radiopharmaceuticals labelled with
99mTc have advantages and disadvantages when compared to thallium-201 chloride, as best
rate of counts and less sensitivity to assess viability, respectively.
The stress phase can be accomplished by exercise or by the use of drugs such as dipyrida‐
mole, adenosine, and dobutamine. The sensitivity and specificity of these types of stress are
similiar.
Clinical applications of the study with thallium-201 chloride are: diagnosis of coronary ar‐
tery disease, assessing the extent and severity of coronary stenosis, myocardial viability as‐
sessment and therapeutic efficacy (CABG and angioplasty).
Radiopharmaceutical labelled with 99mTc are usually associated with cardiac monitoring
during image acquisition, thus allowing quantitative analysis with motility evaluation of the
left ventricular wall and ejection fraction.
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Clinical applications of the study using radiopharmaceuticals labelled with 99mTc are: a
diagnosis  of  coronary  artery  disease,  risk  stratification  post-myocardial  infarction  and
therapeutic efficacy (Figure 6).
Figure 6. Myocardial perfusion scintigraphy with 99mTc-sestamibi. A: Pre-angioplasty: ischemia of the apex and the
middle and apical regions of the anteroseptal wall of the left ventricle. B: Post-angioplasty: a study without evidence
of myocardial ischemia.
3.2. Myocardial viability imaging
The principle objective of myocardial viability assessment is to identify patients eligible for
coronary artery bypass grafting (CABG). Several criteria were used to determine the clinical
impact of CABG: improvement in regional left ventricular function, in global left ventricular
function (ejection fraction), symptoms, functional capacity, in cardiac remodeling and long
term prognosis [1].
Imaging with thallium-201 chloride and home-redistribution protocol can be used to assess
the presence of viable myocardium. Using the protocol stress-rest-reinjection, in addition to
similar information, the presence of ischemia can be evaluated.
3.3. Myocardial infarction imaging
Currently this study has been little used, due to advances in methods of enzymatic detection
of acute myocardial infarction. Radiopharmaceuticals used can be 99mTc-pyrophosphate
and Antimyosin-Fab-DTPA-In-111.
The maximum uptake of 99mTc-pyrophosphate occurs 24 to 72 hours after the event. Planar
imaging with 99mTc pyrophosphate detect acute transmural with a sensitivity of at least
90% and a specificity of 70% (Figure 7). Tomographic imaging (SPECT) can improve the spe‐
cificity to around 80%.
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 Figure 7. Imaging of myocardial infarction with 99mTc-pyrophosphate. 99mTc: trasmural infarction in the anterolat‐
eral wall of the left ventricle.
Antimyosin has an overall sensitivity of 92% for the detection of acute MI [2].
3.4. Multi Gated Acquisition (MUGA)
The objective is to assess the global and regional ventricular function. The radiopharmaceut‐
ical used is 99mTc-red blood cells (RBC), erythrocytes labeled with 99mTc. The parameters
evaluated in this study are: motility of the ventricular wall, left ventricular ejection fraction,
analysis of phase and amplitude. The clinical indications are: acute myocardial infarction,
coronary artery disease, cardiomyopathy, valvular disease, congenital heart disease, thera‐
peutic efficacy assessment and evaluation of cardiotoxic drugs.
3.5. Cardiac adrenergic imaging
The sympathetic and parasympathetic innervation of the heart plays an important role in
regulating the cardiac function [3]. The activation of sympathetic innervation causes in‐
creased heart rate (chronotropic effect), contractility (inotropic effect) and conduction atrio‐
ventricular [4]. Norepinephrine is produced and stored in presynaptic vesicles in
sympathetic nerve terminals [5]. Thus, the radionuclide used for cardiac adrenergic imaging
is 123I-MIBG (metaiodobenzylguanidine) that is an guanethidine analogue which mimics
norepinefrina [6]. The clinical indications are: heart failure, cardiomyopathy, cardiac trans‐
plantation, ischemia and myocardial infarction and ventricular tachyarrhythmias.
4. Pulmonary system
Pulmonary embolism (PE) is an important and treatable illness caused by migration of
thrombus to the pulmonary circulation, commonly from the veins of the lower extremities.
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Untreated, PE can cause death [7]. The treatment includes oral anticoagulants, heparin and
thrombolytic agents. The clinical presentation of PE is variable, from asymptomatic to sud‐
den death, including cough, hemoptysis, chest pain, breathlessness, syncope, palpitations,
tachypnoea, cyanosis, tachycardia, pulmonary hypertension and right heart failure. But,
these symptoms are not specific of PE, needing more tests to confirm or refuse the PE diag‐
nostic. Recently, Bajc et al, purposed a clinical algorithm for the investigation of patients
with suspected PE. If the clinical likelihood of PE is low and the quantitative D-dimer is neg‐
ative, a diagnosis of PE is unlikely and further investigations are not required. If the clinical
likelihood of PE is low and the quantitative D-dimer is positive, further investigations for a
range of diagnoses including PE may be required, particularly if the D-dimer level is mark‐
edly elevated. If the clinical probability is other than low, it seems more appropriate to skip
the D-dimer test and refer the patient directly to the appropriate imaging technique. This
may be Ventilation (V) and perfusion (P) imaging (V/PSCAN) or multidetector computed to‐
mography of the pulmonary arteries (MDCT) depending on the local availability, medical
expertise, and the patient’s clinical condition. V/PSCAN has virtually no contraindications and
yields a substantially lower radiation burden than MDCT [8].
A combined ventilation and perfusion study increases the specificity for PE diagnosis. A
combined 1-day protocol is preferred. The scan can be with planar lung imaging (anterior,
posterior, left and right lateral and left and right posterior oblique) or Spect imaging. In
pregnancy only a perfusion scan is recommended.
4.1. Ventilation lung scintigraphy (V)
Ventilation studies, in general, are performed after inhalation of inert gases 133Xe and 81mKr,
radiolabelled aerosols 99mTc-DTPA and 99mTc-labelled Technegas. It is performed for map‐
ping regional ventilation.
4.2. Perfusion lung scintigraphy (P)
Perfusion scintigraphy is accomplished by microembolization with radiolabelled particles
injected into a peripheral vein. The commercially used particles are MAA, which are label‐
led with 99mTc. The particle distribution accurately defines regional lung perfusion.
V/PSCAN exploits the unique pulmonary arterial segmental anatomy. Each bronchopulmona‐
ry segment is supplied by a single end-artery. In principle, conical bronchopulmonary seg‐
ments have their apex towards the hilum and base projecting onto the pleural surface.
Occlusive thrombi, affecting individual pulmonary arteries, therefore produce characteristic
lobar, segmental or subsegmental peripheral wedge-shaped defects with the base projecting
to the lung periphery. V/P mismatch within bronchopulmonary segment(s) defected by PE,
ventilation is usually preserved. This pattern of preserved ventilation and absent perfusion
within a lung segment gives rise to the fundamental signiture for PE diagnosis using V/
PSCAN, known as V/P mismatch.
Follow-up of PE using imaging is essential to assess the effect of therapy, differentiate be‐
tween new and old PE on suspicion of PE recurrence and investigate physical incapacity af‐
ter PE [9].
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 Figure 8. Normal pulmonary scintigraphy.Inhalation and perfusion images are compared. Homogeneous uptake in
lungs. Matched findings.
5. Genitourinary tract imaging
In nuclear medicine the studies of genitourinary system can be divided into superior and
inferior genitourinary tract. Studies evaluating the superior genitourinary tract include the
kidneys, allowing evaluation of several characteristics such as blood flow, function, anato‐
my and integrity of the collection system, aiding in the diagnosis of different pathologies.
For the lower genitourinary tract studies are represented by radionuclide cystography and
testicular scintigraphy.
Renal radiopharmaceuticals commonly used to meet the various pathologies are 99mTc-
MAG3, 99mTc-DTPA, 99mTc-GHA and 99mTc-DMSA, being dependent on the indication
of particular characteristics. 99mTc-MAG3 has as a main uptake mechanism tubular secre‐
tion (98% tubular secretion, 2% of glomerular filtration and extraction fraction of 40-50%).
the 99mTc-DTPA has as a main uptake mechanism glomerular filtration (100% filtration and
extraction fraction of 20%). 99mTc-GHA has a mixed uptake mechanism, being, glomerulo-
tubular (10-20% tubular secretion and 80-90% glomerular filtration). The 99mTc-DMSA is at‐
tached to the renal cortical (40-50% cortical binding in 2 hours).
5.1. Clinical applications in the superior genitourinary tract
Dynamic renal scintigraphy renogram represents the study commonly used to evaluate the
various pathologies associated with superior genitourinary tract.
5.1.1. Obstruction of the genitourinary tract
It is the main indication of renal dynamic studies. The exam is simple, painless, easy to per‐
form and only prior hydration is necessary. It lasts 30 to 50 minutes, and such variation is
associated with the use of diuretics (Figures 9 and 10).
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Figure  9.  Dynamic  renal  scintigraphy  with  99mTc-DTPA:  flow,  normal  function  and  nonobstructive  excretory
pathways.
5.1.2. Hypertension of renovascular origin
For this condition, the renal dynamic study is done in two phases: one utilizing a stimulus
by angiotensin converting enzyme inhibitor, one hour before administration of the radio‐
pharmaceutical and the other from the merely studying renal dynamic without stimulus
considered study baseline.
According to the pathophysiology of renovascular disease, the standard pattern of diagnosis
is an abnormal study with stimulation of the angiotensin converting enzyme inhibitorassoci‐
ated with a normal baseline study.
5.1.3. Renal transplant
In renal transplant, renal dynamic study is mainly used for evaluation of its most common
complications such as acute tubular necrosis and rejection. The scintigraphic pattern of acute
tubular necrosis and acute rejection are very similar, with preserved or slightly reduced
flow and reduced glomerular filtration rate. The time and symptoms are the key to diagno‐
sis. In serial renal studies, the renal graft dysfunction secondary to acute tubular necrosis
should improve or remain unchanged, while the rejection demonstrates progressive deterio‐
ration. Currently, ultrasound is the method of choice for renal transplant dysfunction [10].
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 Figure 10. Dynamic renal scintigraphy with 99mTc-DTPA and use of diuretic: Deficit of flow and left renal function
associated with obstructive hydronephrosis.
5.1.4. Acute pyelonephritis and renal scarring
The renal cortical scintigraphy with 99mTc-DMSA is the procedure of choice for evaluating
acute pyelonephritis and renal scarring. The image acquisition takes place 2 to 3 hours after
intravenous administration of the radiopharmaceutical so that attachment occurs at the
same cortical. The scintigraphic patterns in acute pyelonephritis are focal involvement of a
Clinical Applications of Nuclear Medicine
http://dx.doi.org/10.5772/53029
49
single area or multiple areas and diffuse involvement of the kidney. It has 100% sensitivity
and specificity above 87% [11].
Renal scarring is a consequence of acute pyelonephritis, which may develop in 37% to 80%
of children after an episode of infection [11,12] (Figures 11 and 12).
 
Figure 11. Normal renal scintigraphy with 99mTc-DMSA.
 
Figure 12. Renal scintigraphy with 99mTc-DMSA, renal scars.
5.2. Clinical applications in the lower genitourinary tract
5.2.1. Assessment of vesicoureteral reflux
Radionuclide cystography permits visualization of very small volumes of reflux, and is
probably more sensitive than contrast cystography [13]. The procedure is performed by in‐
fusion of saline and radiopharmaceuticals within the bladder through the catheter, thereby
evaluating the presence of reflux (Figure 13).
5.2.2. Testicular torsion
Testicular torsion is considered a surgical emergency and the availability of this tissue is
mainly related to ischemic time. The testicular ultrasound is a simple method and easily per‐
formed for evaluation of this condition, however, in children evaluating the flow can be dif‐
ficult, testicular scintigraphy is indicated.
The scintigraphic findings depend on the stage of testicular torsion, in the early phase there
is a normal flow, reduced or absent and the still image is a slight reduction in uptake of the
radiotracer within the testicle, followed by an increase in flow and static image appearance
of halo of mildly increased activity around a centrally cold testicle, ending with testicular
infarction, in which there is an increased flow rate and persistent halo of increased activity
around a cold center.
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Figure 13. Radionuclide cystography: right vesicoureteral reflux.
6. Musculoskeletal system
6.1. Bone scintigraphy
Bone scintigraphy identifies single or multiple focal or diffuse areas with increased osteo‐
blastic activity, which reflects local bone remodeling. It is a highly sensitive examination for
detecting such abnormalities, but its specificity is limited. It needs to be analyzed in conjunc‐
tion with other imaging examinations. It is indicated for both adults and children, but
should be interpreted differently for these two groups, given that the normal distribution of
radiopharmaceutical in the skeleton differs between adults and children, particularly be‐
cause of the presence of physiological osteoblastic activity in the growth cartilage of chil‐
dren. These bone scans are based on the principle of phosphonate uptake in bone tissue,
especially in blastic lesions. For example, from this principle, the presence of osteoblastic
metastases from breast tumors or prostate tumors can be seen, among others. Likewise,
changes typical of benign diseases such as bone infections, inflammatory activity of rheu‐
matic diseases, and prosthesis complications like loosening, infection, etc., can be seen.
The radiopharmaceutical used most, which is called 99mTc-methylene diphosphonate (99mTc-
MDP), binds to the amorphous phase of hydroxyapatite crystals by means of chemoadsorp‐
tion. It is administered intravenously as a bolus. Images can be acquired immediately
afterwards when information on the blood supply and vascular permeability is important,
like in cases of infectious or tumor growth processes. They may also only be acquired later
on, after 2-3 hours of injection, with acquisition of whole-body images in the anterior and
posterior projections, in order to acquire information on osteoblastic activity. It is worth em‐
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phasizing that this examination shows low sensitivity to predominantly lytic pathological
conditions or to conditions with low bone remodeling, except in cases associated with signif‐
icant osteoblastic abnormalities, such as in investigations of associated fractures, for exam‐
ple, in patients with multiple myeloma. The great advantage of this method is that it
assesses the whole body in a single examination with high sensitivity, and it guides other
examinations that are more specific.
6.1.1. Clinical applications for children
Based on informations above, the mean indications of bone scan include: primary benign or
malignant bone tumors and bone metastases; acute osteomyelitis versus soft-tissue inflam‐
mation; subacute and chronic osteomyelitis; septic arthritis as a complication of osteomyeli‐
tis; and aseptic arthritis; aseptic necrosis (Legg-Calvé-Perthes disease) and sickle cell disease;
equivocal radiographic findings after trauma; stress fractures; occult fractures; child abuse;
multiple trauma; complications of fractures and therapy; and Sudeck’s atrophy; surgery‐
guided by bone scintigraphy, like as osteoid osteoma; bone dysplasia; Camurati-Engelmann
disease; evaluations on skeletal involvement (brown tumors); and hyperparathyroidism; ar‐
thritis and bone pain [14]. Scintigraphies in children are showed in figure 14.
 A B C 
Figure 14. Bone scintigraphy in children. A. normal scan: Symmetric uptake on the skeletal and presence of physiolog‐
ical osteoblastic activity in the growth cartilage. B. Acute phase of avascular necrosis in right femoral head. Vascular
permeability decreased (green arrow) and photopenic area (brown arrow) in right femoral head. C. Three phase bone
scan. Osteosarcoma in the right humerus. Flow, vascular permeability and osteoblastic activity increased in right hu‐
merus (red arrows).
6.1.2. Clinical applications for adults
A little difference is observed between the chindren`s and adults`indications of bone scan. In
this last group, the pathologies include: primary and metastatic bone tumors: staging, fol‐
low-up and post-therapy evaluation; distribution of osteoblastic activity prior to radiometa‐
bolic therapy (89Sr, 153Sm-EDTMP and 186Re-HEDP); osteomyelitis; Paget’s disease,
osteoporosis and hyperparathyroidism; arthropathy, low back pain and sacroiliitis; fibrous
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dysplasia and other rare congenital conditions; stress fractures, shin splints, occult fractures;
avascular necrosis and loose or infected joint prosthesis [15] (Figure 15).
 B A C D E 
Figure 15. Bone scintigraphies in adults. A. Normal scan: symmetric uptake on the sckeletal. B. Single bone metastasis
on left rib. C. Multiple bone metastasis. Multiple focal uptake on skull, scapulas, ribs, spine, pelvis and right femur. D.
Monostotic Paget Disease on right humerus. Intense uptake on right humerus. E. Hyperparathyroidism. Intense uptake
on skull and focal uptake on ribs.
7. Scintigraphy with gallium-67 citrate
Because of the characteristics of gallium-67 uptake in tissues, this radiotracer can be used in
relation to neoplastic diseases, especially lymphomas, and in cases of chronic inflammatory
or infectious processes, such as those in fever of unknown origin or in patients with ac‐
quired immunodeficiency.
The radiotracer is administered intravenously 48 hours before producing whole-body initial
images in the supine position, in the anterior and posterior projections. Delayed images,
produced at least from 72 hours and up to 5 days after injection, may be needed to differen‐
tiate normal colonic activity from lesions in the abdomen. This allows clearance of nonspe‐
cific activity from the body, and enhancement of the target in relation to the background in
the images. The technologist or physician should give the patient a thorough explanation
about the examination. Food and liquid restrictions are not mandatory. Bowel preparation is
optional. In patients with constipation, oral laxatives prior to imaging may decrease the ac‐
tivity in the bowel. In this case, laxatives should be given on the day before gallium-67 scin‐
tigraphy (at least 18 hours prior to scanning). Gallium-67 scanning should be avoided within
24 hours of blood transfusion or gadolinium-enhanced MRI, which could interfere with gal‐
lium-67 biodistribution. It is also advisable to wait 3-4 weeks after chemotherapy before per‐
forming follow-up imaging.
Management of patients with lymphoma is very useful, especially in intermediate or high-
grade tumors. Low-grade lymphomas may not uptake gallium-67 and therefore may not
benefit from this method. Although anatomical diagnostic methods such as CT and MRI are
superior to gallium-67 for initially staging the patients, an initial examination using galli‐
um-67 is important because it serves as the basis for post-therapy monitoring of patients and
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indicates which patients may benefit from this method. If the tumor does not concentrate
gallium-67 in the first examination, this radiotracer should not be used for the follow-up.
For lymphomas that concentrate gallium-67, this tool becomes very useful for assessing the
response to the treatment, since gallium accurately assesses tumor viability and the extent of
the disease, indicates the prognosis and, especially, is important for restaging, given that the
anatomical changes that occur after the treatment make it difficult to interpret anatomical
images. Other tumors that may benefit from this method are lung cancer, head and neck tu‐
mors, hepatocellular carcinoma, germ cell tumors, neuroblastomas, sarcomas, multiple mye‐
lomas and melanomas. These tumors present avidity for gallium-67, but the use of this
imaging method in these tumors is not well defined (Figure 16).
BA C D E
Figure 16. Whole body scan with gallium 67. A. normal scintigraphy. B. Lymphoma with lymphonodopathy. Uptake in
left axillary lymphonode. C. Lymphoma with lymphonodapathy in right axillary, supravicular and mediastinal chain
and left lung. D. Lymphoma in inguinopelvic lymphonode and soft tissue in right leg.
In addition, gallium-67 has been used to detect infections or inflammations such as osteo‐
myelitis, sarcoidosis and myocarditis, and to evaluate interstitial lung disease and examine
patients with acquired immunodeficiency syndrome (AIDS). It has been suggested that gal‐
lium-67 may be clinically useful for assessing adults presenting fever of unknown origin be‐
cause of the possibility of locating pathological uptake (both malignant and benign).
Precautions need to be taken in relation to cases of suspected or confirmed pregnancy. If di‐
agnostic procedures are performed on such patients, a clinical decision weighing the bene‐
fits against the possible harm from carrying out the procedure is necessary. Moreover, if
diagnostic procedures are performed on breastfeeding mothers, the breastfeeding should be
discontinued.
Because of the high radiation exposure, children aged less than 14 years should not undergo
gallium-67 scintigraphy, except when there is clear evidence of malignancy.
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In laboratories with PET/CT the gallium scintigraphy was replaced by 18F-FDG in the path‐
ologies described above, because of the best accuracy of the PET.
8. Scintimammography
Scintimammography was approved by the FDA in 1987 as a complementary examination
for use when mammography is indeterminate in investigating malignant breast tumors. It is
not used for screening, although new technologies for the equipment have improved the ac‐
curacy of this method. On the other hand, it is now indicated when mammography presents
limitations in investigating tumor processes, such as in cases of dense breasts, asymmetrical
density, architectural distortion acquired after the procedures or belonging to the breast, de‐
tection of tumor viability or recurrence, and very small breasts, particularly in men when
breast compression cannot be performed. Lymph node status is also assessed, although with
low sensitivity. 99mTc-Sestamibi (a cation with affinity for malignant tumor processes) is
used, with summing of factors such as negative transmembrane potential, activity, mito‐
chondrial density, cell count and cell mitotic activity.
Figure  17.  Scintimammgraphy.  Breast  carcinoma  in  right  and  left  side  (black  arrows)  and  lymphonodal  meta‐
stase (red arrow).
9. Dacryoscintigraphy
This examination is indicated for cases of epiphora. It is a simple and easy-to-perform ex‐
amination, with administration of microdrops of pertechnetate in the epicanthus of the eyes.
In a normal examination, the radiotracer is expected to progressively pass through the pal‐
pebral fissure, lacrimal canaliculi, lacrimal sac, nasolacrimal ducts and nasal cavity. The re‐
tention or obstruction patterns do not show progression of the radiotracer.
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Figure 18. Dacrioscintigraphy. Normal exam. Radiotracer reachs right nasal cavity (black arrows). Total retention in
billateral lacrimal sacs. Right lacrimal sac (red arrows) and left lacrimal sac (light blue arrows).
10. Radioguided procedures
Radioguided procedures were introduced in the 80s, and are based on the search of concen‐
trated lesions of radioactive material guided by a small detector. There are three types of
procedures: the search for occult and/or radioguided lesion (ROLL), the search of sentinel
lymph node (SLN), and the association of the two methods (SNOLL).
ROLL are lesions with difficult to be found when is necessary to be located for biopsy. The
mean indications are: nonpalpable breast lesions, like a small lesions, deep lesions or micro‐
calcifications; for biopsy of parathyroid, osteoma, bone metastasis and so on.
SNL is the first lymph node to be reached by neoplasms cells from the primary tumor. When
the lymph node was not metastatic, the second lymph nodes are not. Then, the total lym‐
phadenectomy can be avoided (Figure 19 and figure 20).
Figure 19. Breast lymphoscintigraphy. Anterior and left lateral images. After injection of radiopharmaceutical sub‐
stance in left breast (yellow arrows) and SLN in left axillary lymphatic chair ( light blue arrows).
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 Figure 20. Billateral breast lymphoscintigraphy. Two sentinel lymph nodes are identified in left and in right axillary
lymphatic chain.
11. Therapy
11.1. Therapy with radioiodine
Radioiodine therapy consists of oral administration of iodine-131 to treat benign and malig‐
nant diseases of the thyroid. Iodine-131 is a beta-emitting radionuclide with a physical half-
life of 8.1 days. The main gamma rays have energy of 364 keV and the beta radiation has
maximum energy of 0.61 MeV, mean energy of 0.192 MeV and tissue reach of 0.8 mm. Be‐
cause of cellular damage it is necessary to have some precautions.
Mean absolute contraindications include: Pregnancy: Female patients of fertile age should
ideally undergo a pregnancy test 72 hours or less before radioiodine therapy. Occasionally,
when the patient’s history clearly demonstrates that there is no possibility of pregnancy, the
test may not have to be done; Breastfeeding: Patients who are breastfeeding have to be ad‐
vised to postpone radioiodine therapy until lactation ceases. This has the aim of minimizing
the radiation absorbed by the breast. Lactation ceases between four and six weeks after de‐
livery when there is no breastfeeding, and four to six weeks after the end of breastfeeding.
This milk should not be stored.
Mean relative contraindications are: Urinary incontinence that is difficult to manage: The
physician should obtain confirmation of the patient’s urinary incontinence in order to take
the necessary measures to avoid contamination through the urine; uncontrollable hyperthyr‐
oidism; active exophthalmia.
The clinical indications for benign disease of thyroid including: hyperthyroidism: Graves’
disease, toxic multinodular goiter and autonomous nodules; non-toxic multinodular goiter:
therapy with iodine-131 has been successfully used to reduce non-toxic multinodular goiter
[15,16](Figure 21).
And for malignant thyroid diseases, specially for: well-differentiated neoplasms of the thy‐
roid that synthesize thyroglobulin. In these cases, iodine-131 has been used to ablate the re‐
mains of the thyroid after total thyroidectomy, and to treat residual cancer and metastatic
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disease after total thyroidectomy. Cerebral metastases have to be assessed carefully, since
there is a risk of bleeding and cerebral edema. In general, the more invasive the cancer is,
the bigger the dose will be.
Figure 21. Thyroid scintigraphies. A. Graves’ Disease. Diffuse thyroid uptake. B. Plummer’s Disease. Nodular uptake on
left thyoid lobe with suppression of the gland.
Figure 22. Whole body scan post radioiodine therapy. Radioidine on thyroid tissue and on cervical lymphodes (red
arrows). In another patient, notice lymphonode (green arrows and lung (light blue arrows) metastasis.
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11.2. 131I-meta-iodobenzylguanidine therapy (131I-mIBG)
This consists of 131I-mIBG intravenous infusion, selectively accumulated by neuroectoder‐
mal tissue, including tumours of neuroectodermal origin. Uptake occurs by active via and
passive diffusion. mIBG is a meta isomer of the guanethidine derivative iodobenzylguani‐
dine, stored within cytoplasmic storage granules and 131I.
Common indications include: neuroectodermal tumours derived from the primitive neural
crest, and showing uptake and retention of labeled mIBG, especially in inoperable or malig‐
nant phaeochromocytoma (Figure 23), inoperable or malignant paraganglioma, inoperable
or malignant carcinoid tumour Stage III or IV neuroblastoma, inoperable, malignant medul‐
lary thyroid cancer.
Figure 23. Phaeochromocytoma. Focal uptake in posterior abdomen aspect (red arrows). Late images are better to
identify the lesion.
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11.3.Treatment of refractory metastatic bone pain
Bone pain is a common symptom of metastatic disease in cancer, experienced with vari‐
ous intensities during the development of their disease, generally in the terminal phases.
In addition to other therapies, such as analgesics, bisphosphonates, chemotherapy, hormo‐
nal therapy and external beam radiotherapy, bone-seeking radiopharmaceuticals are also
used for the palliation of pain from bone metastases (Figure 24). Substantial advantages of
bone palliation radionuclide therapy include the ability to simultaneously treat  multiple
sites of disease with a more probable effect in earlier phases of metastatic disease. The tis‐
sue destruction is also based on beta-emitting radionuclide. This therapy consists of intra‐
venous administration of  89Sr-chloride in aqueous solution,  153Sm-EDTMP or 186Re-HEDP
that reaches the osteoblastic or mixed metastasis from prostate, breast, lung or any other
tumor with osteoblastic presentation. Caution is necessary because this therapy develops
myelotoxicity. Usually the bone pain decreased after two weeks depending on the radio‐
nuclide administered [17].
Figure 24. Bone scan. Bone metastasis.Multiple focal uptake on skeletal,
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12. Conclusion
In conclusion, the information about the nuclear medicine applications, based on metabolic
and functional evaluations, make this method a co-adjuvant of the others anatomic exams
on investigation of many pathologies, without competition with them and being preferred
on the functional lesion follow up, metastasis screening and viable tumor issue.
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